United States - English - NLM (National Library of Medicine)

avera mckennan hospital - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 100 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - morphine sulfate pentahydrate 100mg;   - modified release capsule - 100 mg - active: morphine sulfate pentahydrate 100mg   excipient: dibutyl sebacate ethylcellulose gelatin   macrogol 4000 purified talc sugar spheres titanium dioxide - for the prolonged relief of chronic, moderate to severe pain in adults. use in non-malignant pain: the use of m-eslon sr tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: o all other conservative methods of analgesia have been tried and have failed; o the pain is having a significant impact on the patient's quality of life; o there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 60 mg

United States - English - NLM (National Library of Medicine)

stat rx usa llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 60 mg - ms contin tablets are a controlled-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. ms contin tablets are not intended for use as a prn analgesic. the ms contin 100 and 200 mg tablet strengths are high dose, controlled-release, oral morphine formulations indicated for the relief of pain in opioid-tolerant patients only. ms contin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established. ms contin is not indicated for pain in the postoperative period if the pain is mild, or not expected to persist for an extended period of time. ms contin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist

United States - English - NLM (National Library of Medicine)

zyla life sciences us inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - arymo er is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions (5.1)] , reserve arymo er for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - arymo er is not indicated as an as-needed (prn) analgesic. arymo er is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.3)] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.6)] - concurrent use of m

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 60 mg

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 10 mg - kadian is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions ( 5.1 )] , reserve kadian for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - kadian is not indicated as an as-needed (prn) analgesic. kadian is contraindicated in patients with - significant respiratory depression [see warnings and pre cautions ( 5.2 )] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [s ee warnings and precautions ( 5.5 )] - concurrent use of m

United States - English - NLM (National Library of Medicine)

par pharmaceutical inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 20 mg

United States - English - NLM (National Library of Medicine)

stat rx usa llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 20 mg - kadian® capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time (see clinical pharmacology). kadian ® capsules are not intended for use as a prn analgesic. kadian® is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild or not expected to persist for an extended period of time. kadian® is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (see american pain society guidelines.) kadian® is contraindicated in patients with a known hypersensitivity to morphine, morphine salts or any of the capsule component

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 20 mg - kadian® capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time (see clinical pharmacology). kadian® capsules are not intended for use as a prn analgesic. kadian® is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild or not expected to persist for an extended period of time. kadian® is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (see american pain society guidelines.) kadian® is contraindicated in patients with a known hypersensitivity to morphine, morphine salts or any of the capsule components, or